ASPIRE BIOPHARMA HOLDINGS, INC.
Income Statement
| Line Item | FY2025 |
|---|---|
| Revenue | $6.2K |
| Cost of Revenue | $6.3K |
| Gross Profit | $-116 |
| Gross Margin | -1.9% |
| Operating Expenses | |
| Research & Development | $923.9K |
| SG&A Expense | $17.6M |
| Operating Income | $-19.4M |
| Operating Margin | -312,016.9% |
| Interest Expense | — |
| Pretax Income | $-24.5M |
| Income Tax Expense | — |
| Net Income | $-24.5M |
| Net Margin | -394,725.1% |
| EPS (Basic) | — |
| EPS (Diluted) | $-16.38 |
| Shares Outstanding (Basic) | 1.5M |
| Shares Outstanding (Diluted) | 1.5M |
| Dividends Per Share | — |